Previous 10 | Next 10 |
2023-10-17 05:10:00 ET Want to invest in stocks that you can buy and forget about? If so, you'll want to consider companies with plenty of long-term growth opportunities and solid financials. Among the best growth investments that check off those boxes today are Novartis (NYSE: NVS) ...
2023-10-13 18:11:38 ET Summary We rate Alnylam Pharmaceuticals, Inc.'s common stock a Buy on the dip after the complete response letter, CRL for Patisiran. The investment thesis is based on the high probability of success for Vutrisiran, the company's next-generation inverse RNA o...
2023-10-10 14:10:30 ET Summary Initiating RayzeBio, Inc. coverage with a Buy rating and common stock price target of $43 based on my risk-adjusted NPV discounted cash flow model, representing a 110% upside. The company's radiopharmaceutical technology could revolutionize the cance...
2023-10-09 13:10:55 ET More on Bristol-Myers Squibb Company , Mirati Therapeutics Bristol-Myers' Mirati Takeover: Pharma Is Either Buying Crown Jewels Or A Dud Bristol-Myers: Out Of Favor (Rating Upgrade) Bristol-Myers Squibb: How Cheap Is Cheap Enough? ...
2023-10-08 23:00:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2023-10-08 15:18:00 ET As the FDA continues to mull the fate of Amgen's lung cancer drug Lumakras, Sanofi is reportedly moving in on Mirati ( NASDAQ: MRTX ), which has developed a rival product called Krazati. Analysts appear to be divided on whether the FDA will end up denying ...
2023-10-06 18:09:48 ET Summary The biotechnology and pharmaceutical sectors have been under pressure in 2023, with the Invesco Pharmaceuticals ETF down 9% and the iShares Biotechnology ETF down 6%. Elevated interest rates and potential pricing power erosion are the primary headwin...
2023-10-06 00:48:06 ET Summary Ex-Sandoz, Novartis confirmed its yearly guidance and capital allocation priority (DPS growth and buyback). We believe NVS might experience a margin uplift following the spin-off. Sandoz started trading with a market cap of $11.2 billion. The com...
2023-10-04 11:33:44 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Sandoz (OTCMKT: SDZNY ) stock is a hot topic among traders on Wednesday as the company starts trading after a spinoff. Let’s get into everything investors need to k...
2023-10-04 10:26:12 ET More on Novartis Novartis: Buy This Dividend Aristocrat For Consistent Income Novartis: Q2 Beats Expectations, But Still Pricey Novartis: Strong Growth And Continued Expansion For KISQALI Novartis said to be considering a partial sale o...
News, Short Squeeze, Breakout and More Instantly...
2024-07-19 04:04:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-07-18 16:45:16 ET Image source: The Motley Fool. Novartis Ag (NYSE: NVS) Q2 2024 Earnings Call Jul 18, 2024 , 8:00 a.m. ET Operator Continue reading For further details see: Novartis Ag (NVS) Q2 2024 Earnings Call Transcript
2024-07-18 14:15:34 ET By most standards shares of drugmaker Novartis (NYSE: NVS) should be higher following this morning's release of its second-quarter results. The drugmaker's top and bottom lines were both better than expected, and up from year-earlier comparisons. And profit gu...